Propeller Health has signed a development agreement and R&D collaboration with GlaxoSmithKline to develop and manufacture a custom sensor for its Ellipta dry powder inhaler for use in certain GSK clinical studies in asthma and COPD.
In the studies, the sensor will automatically collect and record data on the inhaler’s usage (ie date and time of each use), wirelessly transmitting the information to a central data repository for analysis by GSK’s clinical researchers, Propeller says.
The sensor technology will be used to provide greater insights into adherence patterns across patient populations and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes.
The Propeller platform has been used by patients in over 35 commercial programs across the United States. It is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose inhalers (MDIs), and other inhaler devices (dry powder inhaler (DPI) and soft mist inhaler (SMI)).
“We continue to find new and better ways to conduct clinical trials by exploring novel patient centered outcomes through strategic collaborations,” said Dave Allen, senior vice president of Respiratory R&D at GSK. “Using innovative sensor technology to improve the quality of adherence data collected during our studies will advance our understanding of disease and inform our decision-making in the development of new medicines.”
